Biodyne Co. Ltd.
Biodyne Co., Ltd. engages in the development, manufacture, and sale of liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis in South Korea. The company offers PATHPLORER solution, which preserves and fixes the collected cells; PATHPLORER LBC system, an equipment for processing liquid cytology samples for cancer diagnosis. It exports its products to Japan, Russia, Portugal, … Read more
Biodyne Co. Ltd. (314930) - Net Assets
Latest net assets as of September 2025: ₩42.67 Billion KRW
Based on the latest financial reports, Biodyne Co. Ltd. (314930) has net assets worth ₩42.67 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩43.45 Billion) and total liabilities (₩774.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩42.67 Billion |
| % of Total Assets | 98.22% |
| Annual Growth Rate | 116.23% |
| 5-Year Change | 516.95% |
| 10-Year Change | N/A |
| Growth Volatility | 533.58 |
Biodyne Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how Biodyne Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biodyne Co. Ltd. (2018–2024)
The table below shows the annual net assets of Biodyne Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩43.20 Billion | -0.42% |
| 2023-12-31 | ₩43.38 Billion | -1.76% |
| 2022-12-31 | ₩44.16 Billion | +14.70% |
| 2021-12-31 | ₩38.50 Billion | +449.81% |
| 2020-12-31 | ₩7.00 Billion | +6.48% |
| 2019-12-31 | ₩6.58 Billion | +1457.40% |
| 2018-12-31 | ₩422.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biodyne Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1270747860000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩14.88 Billion | 34.45% |
| Other Components | ₩43.78 Billion | 101.34% |
| Total Equity | ₩43.20 Billion | 100.00% |
Biodyne Co. Ltd. Competitors by Market Cap
The table below lists competitors of Biodyne Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chien Kuo Construction Co Ltd
TW:5515
|
$144.26 Million |
|
Vuzix Corp Cmn Stk
NASDAQ:VUZI
|
$144.28 Million |
|
PLAYTIKA HOLDING DL-01
F:8II
|
$144.28 Million |
|
SmarTone Telecommunications Holdings Limited
PINK:STTFF
|
$144.30 Million |
|
Namchow Food Group (Shanghai) Co. Ltd.
SHG:605339
|
$144.21 Million |
|
Voxel S.A.
WAR:VOX
|
$144.21 Million |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
$144.18 Million |
|
Tracsis plc
PINK:TCIIF
|
$144.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biodyne Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 43,382,132,590 to 43,199,550,540, a change of -182,582,050 (-0.4%).
- Net income of 10,770,170 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩10.77 Million | +0.02% |
| Other Changes | ₩-193.35 Million | -0.45% |
| Total Change | ₩- | -0.42% |
Book Value vs Market Value Analysis
This analysis compares Biodyne Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 131.37x to 8.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩94.16 | ₩12370.00 | x |
| 2019-12-31 | ₩1466.51 | ₩12370.00 | x |
| 2020-12-31 | ₩1432.45 | ₩12370.00 | x |
| 2021-12-31 | ₩6546.40 | ₩12370.00 | x |
| 2022-12-31 | ₩7508.91 | ₩12370.00 | x |
| 2023-12-31 | ₩1471.74 | ₩12370.00 | x |
| 2024-12-31 | ₩1465.55 | ₩12370.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biodyne Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.20%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.03x
- Recent ROE (0.02%) is above the historical average (-62.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -326.83% | -36.60% | 0.29x | 30.59x | ₩-1.42 Billion |
| 2019 | -30.82% | -49.55% | 0.18x | 3.54x | ₩-2.68 Billion |
| 2020 | -63.62% | -121.34% | 0.15x | 3.61x | ₩-5.15 Billion |
| 2021 | -28.20% | -288.50% | 0.08x | 1.19x | ₩-14.71 Billion |
| 2022 | 12.71% | 45.96% | 0.27x | 1.03x | ₩1.20 Billion |
| 2023 | -2.29% | -24.26% | 0.09x | 1.01x | ₩-5.33 Billion |
| 2024 | 0.02% | 0.20% | 0.12x | 1.03x | ₩-4.31 Billion |
Industry Comparison
This section compares Biodyne Co. Ltd.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $388,417,094,643
- Average return on equity (ROE) among peers: -90.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biodyne Co. Ltd. (314930) | ₩42.67 Billion | -326.83% | 0.02x | $144.24 Million |
| DIO Corporation (039840) | $194.43 Billion | 1.70% | 0.89x | $94.83 Million |
| Cellumed Co. Ltd (049180) | $5.18 Billion | -719.12% | 11.54x | $32.46 Million |
| SD Biosensor Inc (137310) | $2.20 Trillion | 48.32% | 0.36x | $174.83 Million |
| Dentium (145720) | $291.10 Billion | 19.06% | 0.96x | $192.13 Million |
| M.I.TECH Co.Ltd (179290) | $14.71 Billion | 4.08% | 0.17x | $45.98 Million |
| JETEMA Co. Ltd (216080) | $-5.04 Billion | 0.00% | 0.00x | $148.99 Million |
| HASS Corp (450330) | $15.15 Billion | 11.85% | 0.93x | $11.51 Million |